Amrita Y. Krishnan, MD, FACP and Nina Shah, MD
In this video, “Evolving Landscape in Multiple Myeloma”, Amrita Y. Krishnan, MD and Nina Shah, MD consider clinical implications of newer myeloma therapies and regimens – now and for the future.
With many treatment options approved for myeloma, there is no single optimal strategy for all newly diagnosed patients. The therapeutic landscape is complex, and it continues to evolve as new clinical data become available. New strategies to optimize induction, transplant, consolidation, and maintenance regimens by moving newer therapies (e.g., daratumumab) upfront are rapidly emerging. Ongoing studies are better defining the roles of MRD in myeloma assessment and management. Opportunities and challenges for BCMA-directed therapies within the current landscape are discussed.